Keeping the mRNA at its normal, longer length reduced the amount of SPSB1 protein produced by the cancer cells. This allowed the MHC-1 complex to return.

Once the MHC-1 complex was restored, immune checkpoint therapy became much more effective against the prostate tumors. The researchers also performed a detailed analysis of the results and found no detectable off-target effects from the experimental CRISPR treatment.